IM
$10.13
+0.45
(+4.65%)
As of Oct 5, 2026, 4:21 PM EDT
Price history
Immix Biopharma (IMMX) is trading up at $10.13 (+4.65%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: December 16, 2021 · $5.00 offering · NASDAQ · View IPO details →
Immix Biopharma net income history (FY2020–FY2025)
Net income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$453.9K | −$1.35M | −$8.22M | −$16.1M | −$22.7M | −$30.0M |
| Net income | −$1.15M | −$24.4M | −$8.23M | −$15.4M | −$21.6M | −$29.4M |
| EPS (diluted) | −$0.34 | −$6.64 | −$0.59 | −$0.89 | −$0.76 | −$0.89 |
| Balance sheet | ||||||
| Cash and equivalents | $391.1K | $17.6M | $13.4M | $17.5M | $17.7M | $93.9M |
| Total assets | $539.6K | $18.2M | $14.9M | $19.9M | $22.9M | $104.8M |
| Total liabilities | $5.27M | $202.0K | $1.75M | $3.72M | $9.70M | $11.0M |
| Shareholders' equity | −$4.73M | $18.0M | $13.2M | $16.4M | $13.3M | $93.8M |
| Cash flow | ||||||
| Operating cash flow | −$404.7K | −$1.59M | −$7.41M | −$11.4M | −$14.6M | −$23.9M |
| Capital expenditure | — | $802 | — | $52.1K | $1.18M | $732.9K |
| Free cash flow | — | −$1.59M | — | −$11.4M | −$15.8M | −$24.7M |
| Share buybacks | — | — | $100.0K | — | — | — |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$7.39M | −$4.99M | −$4.68M | −$6.72M | −$7.66M | −$10.9M | −$10.8M | −$12.5M |
| Net income | −$7.15M | −$4.81M | −$4.54M | −$6.62M | −$7.59M | −$10.7M | −$10.1M | −$11.6M |
| EPS (diluted) | −$0.24 | −$0.15 | −$0.15 | −$0.22 | −$0.24 | −$0.28 | −$0.18 | −$0.18 |
| Balance sheet | ||||||||
| Cash and equivalents | $19.7M | $17.7M | $15.9M | $11.6M | $15.9M | $93.9M | $79.3M | $225.5M |
| Total assets | $25.1M | $22.9M | $19.9M | $15.6M | $20.1M | $104.8M | $95.8M | $239.1M |
| Total liabilities | $7.59M | $9.70M | $10.3M | $11.0M | $11.8M | $11.0M | $11.5M | $10.2M |
| Shareholders' equity | $17.6M | $13.3M | $9.59M | $4.65M | $8.26M | $93.8M | $84.4M | $228.9M |
| Cash flow | ||||||||
| Operating cash flow | −$4.04M | −$1.48M | −$1.69M | −$5.31M | −$5.91M | −$11.0M | −$9.83M | −$11.7M |
| Capital expenditure | $271.5K | $507.2K | $67.7K | $127.6K | $372.5K | $165.1K | $32.5K | $21.0K |
| Free cash flow | −$4.31M | −$1.98M | −$1.75M | −$5.44M | −$6.28M | −$11.2M | −$9.86M | −$11.8M |
From Immix Biopharma's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Immix Biopharma
- Headquarters
- Los Angeles, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International